These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 17545532)

  • 21. [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
    Zhang HG; Cai RG; Chen SS; Wu F; Chu DT
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1462-4. PubMed ID: 17785082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing?
    Drami I; Pring ET; Gould L; Malietzis G; Naghibi M; Athanasiou T; Glynne-Jones R; Jenkins JT
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e540-e552. PubMed ID: 34147322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor.
    Engvall IL; Elkan AC; Tengstrand B; Cederholm T; Brismar K; Hafstrom I
    Scand J Rheumatol; 2008; 37(5):321-8. PubMed ID: 18666027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
    Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
    Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
    Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
    Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
    Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
    J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
    Ueda H; Demizu M; Oosawa M; Chihara S; Nakanishi Y; Maeda C; Yano K; Kimura F; Iwakawa S
    Gan To Kagaku Ryoho; 2009 May; 36(5):789-93. PubMed ID: 19461179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
    Im CK; Jeung HC; Rha SY; Yoo NC; Noh SH; Roh JK; Chung HC
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):315-21. PubMed ID: 18026677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
    Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
    Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
    Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ;
    J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ambulatory activity, body composition, and lower-limb muscle strength in older adults.
    Scott D; Blizzard L; Fell J; Jones G
    Med Sci Sports Exerc; 2009 Feb; 41(2):383-9. PubMed ID: 19127186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer.
    Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Shiozawa S; Katsube T; Naritaka Y; Ogawa K
    Anticancer Res; 2007; 27(3B):1641-4. PubMed ID: 17595789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal prescription method for cancer chemotherapy.
    Vriesendorp HM
    Exp Hematol; 1985; 13 Suppl 16():57-63. PubMed ID: 3857184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy.
    Hung CJ; Kang BH; Chang KM; Kang YY; Yin CH; Lee CC
    BMC Cancer; 2022 Oct; 22(1):1084. PubMed ID: 36271346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity.
    Prado CM; Antoun S; Sawyer MB; Baracos VE
    Curr Opin Clin Nutr Metab Care; 2011 May; 14(3):250-4. PubMed ID: 21415735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity.
    Hoge RHL; Detert Oude Weme SEH; Vervenne WL; van Berlo-van de Laar IRF; van Herpen CML; Roorda L; Mathôt RAA; Jacobs MS; van Erp NP; Jansman FGA
    Ther Drug Monit; 2022 Dec; 44(6):755-761. PubMed ID: 36006609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.